DIRS.INFO The most relevant business & tech news

☆ GEHC stock finally gets some respect after earnings. Those betting against it got slammed
▼ + stars: | 2024-02-06 | by ( Jeff Marks | ) www.cnbc.com time to read: +8 min

Business at GE Healthcare Technologies capped off 2023 on a strong note despite ongoing concerns about China. The quarterly earnings result from GE Healthcare on Tuesday is the best of both worlds. Quarterly commentary In addition to the mid-single-digit organic revenue growth, total company orders increased by 3%. The continued divergence in orders between the two companies suggests GE HealthCare is taking market share in the industry. A GE Healthcare Ltd. BioProcess machine stands on display during the International Pharmaceutical Expo (Interphex) in New York.

Persons: Eli Lilly, GEHC, It's, Jim Cramer, Philips, we're, GEHC's, We're, Jim Cramer's, Jim Organizations: GE Healthcare Technologies, The, Starbucks, GE Healthcare, General Electric, GE HealthCare, Management, JPMorgan Healthcare, Federal Reserve, CNBC, GE Healthcare Ltd, International Pharmaceutical, Bloomberg, Getty Locations: China, ultrasounds, MRIs, New York

☆ Will the 'Magnificent Seven' have another good run in 2024? Morgan Stanley's Mike Wilson weighs in
▼ + stars: | 2023-11-20 | by ( Weizhen Tan | ) www.cnbc.com time to read: +4 min

Much of the gains in the S & P 500 this year can be attributed to the "Magnificent Seven" stocks. The S & P 500 has rocketed nearly 19% in the year to date. His 2024 price target for the S & P 500 is 4,500. But, he said, "There's going to be … a very good stock picking opportunity, probably away from those seven [stocks] … where there should be more opportunities in the 493." "In today's volatile interest rate environment, we see this cohort offering a balance of relative performance stability along with attractive growth properties," Morgan Stanley said.

Persons: Mike Wilson, Morgan Stanley, CNBC's, Wilson, they've, —, we're, we've, barbells, Eli Lilly, Morgan Organizations: Apple, Microsoft, Nvidia, Tesla, Morgan, Microsoft Tech, Keysight Financial, Visa, Mastercard Consumer, Marriott International Pharmaceuticals, Walmart, Costco . Utilities, DTE Energy, Exelon Corporation . Energy, ConocoPhillips, Marathon Oil, Valero Energy Locations: U.S, Morgan Stanley Asia, Singapore

FDA officials don't have the legal authority to force manufacturers to recall their products, and instead rely on companies to “voluntarily” do so. The FDA previously stated it recommended the manufacturer recall the eyedrops on Oct. 25. That suggests agency officials may still be finalizing documentation from the inspection that triggered the latest recall. Agency records show FDA didn't conduct any inspections in India during fiscal year 2021, at the height of the pandemic. CVS Health said in a statement that it previously “stopped the sale in-store and online” of all the eyedrops cited by the FDA.

Persons: “, weren't Organizations: WASHINGTON, CVS Health, Target, Rite, Kilitch Healthcare, Food and Drug Administration, FDA, Healthcare, U.S, Velocity Pharma, Agency, COVID, CVS, Cardinal Health, Delsam Pharma, Centers for Disease Control, CDC, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP Locations: U.S, Kilitch Healthcare India, Mumbai, Farmingdale, N.Y, India, India’s, Tamil Nadu

☆ Bausch Health's decent quarter can't overcome headwind of ongoing patent dispute
▼ + stars: | 2023-11-02 | by ( Zev Fima | ) www.cnbc.com time to read: +4 min

But they aren't enough to overcome the headwind of the company's ongoing patent legislation. Good numbers, but they take a back seat to the legal battle over Bausch drug Xifaxan. Management didn't provide any update on timing for when the remaining 88% of BLCO that Bausch Health owns will be sold off. Management now expects companywide EBITDA in a range of $3.01 to $3.11 billion, versus an earlier range of $3.0 to $3.15 billion. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Persons: Bausch, Xifaxan, BCH's Bausch, companywide, Jim Cramer's, Jim Cramer, Jim, Timothy Fadek Organizations: Health, Revenue, Pharmaceuticals, Norwich Pharmaceuticals, D.C, Norwich, FDA, XIFAXAN, Management didn't, Bausch Health, Management, CNBC, International Pharmaceutical, Bloomberg, Getty Images Bloomberg, Getty Locations: New York, U.S, Interphex

☆ The market is undervaluing this stock — so we're adding to our position
▼ + stars: | 2023-07-18 | by ( Jeff Marks | ) www.cnbc.com time to read: +2 min

As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . A GE Healthcare Ltd. BioProcess machine stands on display during the International Pharmaceutical Expo (Interphex) in New York.

Persons: Jim Cramer's, GEHC, Jim Cramer, Jim Organizations: GE Healthcare Technologies, GEHC, Medicare, GE Healthcare, Alzheimer's, CNBC, GE Healthcare Ltd, International Pharmaceutical, Bloomberg, Getty Locations: New York

☆ Exclusive: Germany's Stada asks Berlin to help secure its future in Ukraine
▼ + stars: | 2023-04-04 | by ( Patricia Weiss | ) www.reuters.com time to read: +2 min

In the March 21 letter to German Economy Minister Robert Habeck, Stada CEO Peter Goldschmidt said there was a risk Kyiv might withdraw the company's market authorisation. Habeck promised investment guarantees for German companies during a trip to Ukraine on Tuesday as part of his goal to speed up reconstruction in the war-torn country. Pharmaceutical companies such as Stada and German rivals Bayer (BAYGn.DE) and Boehringer Ingelheim continue to deliver medicines to the country. Stada is very keen to maintain its presence in Ukraine, Goldschmidt told Habeck. "Therefore, we would like to ask you again for your support and for clear signals in the direction of Ukraine to strengthen German companies there," his letter added.

☆ Bausch Health's stock soars on solid quarterly results, but we have concerns about the recovery
▼ + stars: | 2023-02-23 | by ( Zev Fima | ) www.cnbc.com time to read: +4 min

Bottom line The Canadian specialty pharmaceuticals company reported solid results for the fourth quarter, along with favorable forward guidance. Bausch management on Thursday did not offer additional information, other than to reiterate its confidence in the strength of the company's patents. Bausch Health previously started the separation process via an initial public offering of Bausch + Lomb in May 2022. Results at the diversified products division — which includes neurology pharmaceutical products, generics and dentistry products — were hampered by generic competition. Notably, as Bausch Health owns most of Bausch + Lomb, the latter's financials still appear on Thursday's results.

☆ Saudi bourse falls on Fed worries; Qatar gains
▼ + stars: | 2023-02-19 | by ( Ateeq Shariff | ) www.reuters.com time to read: +1 min

Feb 19 (Reuters) - Saudi Arabia's stock market closed lower on Sunday after U.S. economic data stoked fears the Federal Reserve will act more aggressively to curb inflation. Most Gulf Cooperation Council countries, including Qatar, Saudi Arabia and the United Arab Emirates have their currencies pegged to the U.S. dollar and follow the Fed's policy moves closely, exposing the region to a direct impact from monetary tightening in the world's largest economy. The benchmark index (.TASI) in Saudi Arabia dropped 0.5%, dragged down by a 2.1% slide in Retal Urban Development Co (4322.SE) and a 0.9% decrease Al Rajhi Bank (1120.SE). In Qatar, the index (.QSI) bucked the trend to finish 0.7% higher, led by a 3.4% rise in the Gulf's biggest lender Qatar National Bank (QNBK.QA). ** Markets in Kuwait and Oman were closed for a holidayReporting by Ateeq Shariff in Bengaluru; editing by Barbara LewisOur Standards: The Thomson Reuters Trust Principles.

Search resuls for: "International Pharmaceutical"

8 mentions found